MRX: %COMPANY_NAME% Stock Quote & Analysis - Zacks.com

ESTIMATES
Detailed Estimates

43.96

                        NA: (NYSE: MRX)
                    
                                    $43.98
                                
                                    0.02 (0.05%)
                                
                                    Volume 1,899,018
                                
                                    Dec 10 04:00 PM ET
                                
Zacks Rank: NA  

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                    Zacks Rank
                                                                    Definition
                                                                    Annualized Return
                                                                
                                                                    #1
                                                                    Strong Buy
                                                                    26.6%
                                                                
                                                                    #2
                                                                    Buy
                                                                    18.71%
                                                                
                                                                    #3
                                                                    Hold
                                                                    10.12%
                                                                
                                                                    #4
                                                                    Sell
                                                                    4.32%
                                                                
                                                                    #5
                                                                    Strong Sell
                                                                    2.16%
                                                                
                                                                    S&P
                                                                    500
                                                                    9.93%
                                                                
                                                        Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Overview Quote

                            Get Overview Quote for:
                            
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MRX Chart  by YCharts

                Earnings Estimates
            
                            No data available for MRX
                            
    Zacks Commentary
    
VRX and Gladerma Ink Revised DealDec 06, 2012
Valeant a Step Closer to MedicisNov 20, 2012
Allergan to Buy SkinMedicaNov 19, 2012
Glitch in Medicis-Valeant DealNov 12, 2012
Valeant Beats on All FrontsNov 05, 2012
The Zacks Analyst Blog Highlights: Medicis Pharmaceutical, Valeant Pharmaceuticals International, First Potomac Realty Trust, Ameriprise Financial and First...Oct 16, 2012
Medicis, Revance Settle LitigationOct 15, 2012
Valeant Buys QLT's VisudyneSep 26, 2012
More MRX Zacks Commentary

                        News
                    
Acquisitions Help Valeant Pharma Rise To The Top - Investors Business DailyNov 27, 2012
Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition - BenzingaNov 16, 2012
Medicis Pharmaceutical Corp. Reports Operating Results (10-Q) - GuruFocusNov 9, 2012
Valeant Earnings, Guidance Beat Street`s Estimates - Investors Business DailyNov 2, 2012
Valeant Pharmaceuticals Buys Its Way To The Top - Investors Business DailyOct 18, 2012
Valeant Pharmaceuticals Outpaces Peer Sales Growth - Investors Business DailyOct 12, 2012
Revance Therapeutics Regains All Worldwide Rights to Its Botulinum Toxin Products; Will Make Upfront Payment of $7M, Up to Added $18M Payments; Medicis Will Keep Equity Stake in Revance - BenzingaOct 8, 2012
UPDATE: Morgan Stanley Reiterates Equal-Weight Rating, Raises PT on Medicis Pharmaceutical - BenzingaOct 3, 2012
See All News Stories on MRX

<a href="#"><img id="dart_image_2" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="728" height="90" border="0" alt="" /></a>                

                            Quick Links
                        
Services

                                            Premium Services
Zacks Rank
Personal Finance
Commentary
Education

                                        
My Account

                                            Manage Account
Update Profile
Subscriptions
Preferences
Login/Password Help
Upgrade to Premium

                                        
Resources

                                            Help
FAQs
Disclosure
Privacy Policy
Performance
Site Map

                                        
Client Support

                                            Contact Us
Share Feedback
About Zacks
Careers
Advertise
Media

                                        
Follow Us
Facebook
Twitter
Linkedin
RSS
You Tube
Zacks Research is Reported On:

                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.